Friday, 19 April, 2024
HomeEditor's PickFinnish study calls for review of HPV screening policies

Finnish study calls for review of HPV screening policies

Vaccines that prevent the cancers caused by the human papillomavirus (HPV) are so effective that it may be time to review HPV screening protocols, according to the somewhat provocative conclusion of a recent study examining the occurrence of genital HPV types eight years after immunisation.

The randomised controlled study, published in Cell Host & Microbe, included more than 60 000 women from 33 Finnish communities born in 1992, 1993, and 1994, who were divided into three groups based on their cities’ HPV vaccination strategies: gender-neutral HPV vaccination, girls-only vaccination, and no vaccination.

The researchers then followed up four and eight years after the vaccination to test for 16 types of genital HPV – HPV 16/18/31/45, the high-oncogenic types, and 12 other types carrying lower cancer risk.

STAT News reports that they were looking to establish the most effective immunisation strategy, and to determine what happens after a successful vaccination effort significantly depleted high-cancer-risk HPV types 16/18/31/45.

“This paper paints a nice picture that indeed the vaccine is most efficient when you vaccinate boys and girls. We can see how the different HPV types are distributed in the communities where you have both genders vaccinated, so it is clear that there’s a stronger protection,” said Ville Pimenoff, a senior researcher at the Karolinska Institutet and professor at the University of Oulu in Finland, who was the study’s lead author.

“Apart from the individual vaccination, then you have the herd protection.”

In the group with gender-neutral vaccination, a 50% vaccination coverage per year cohort was sufficient to nearly eliminate the occurrence of high-oncogenic HPV types targeted by the vaccine.

When vaccines are administered exclusively to girls, the uptake needs to be extremely high to reach the same results. Further, HPV45 depletion was observed only in the gender-neutral group.

“Girls-only vaccination for HPV herd immunity requires 90% of girls to be vaccinated year on year since only half of the population is being protected, but immunising boys starts to protect the other half of the population and the virus has nowhere to go,” said Margaret Stanley, emeritus professor of epithelial biology at the University of Cambridge, who was not involved in the study.

At the same time, the samples showed that other HPV types closely related to those targeted by the vaccine had replaced the initial targets.

This is not surprising, said Pimenoff. When you have significant variety in a virus type, as with HPV, removing a subset of it leaves a niche that is free to be easily occupied by the remaining strains, which have evolved in a similar way.

“This work confirms the added value of gender-neutral vaccination and directs a need to be dutiful in monitoring changes in non-vaccine type distributions. It is impossible to know whether the latter will yield any significant threat but the risk is probably very low,” said
Peter Stern, a professor of immunology and cancer biology at the University of Manchester, who was not involved in the study.

Pimenoff said the findings of his study suggest it may be appropriate to rethink screening practices. In a population like Finland’s, he said, there is now a cohort of women who are coming to screening age (which starts as early as 25, depending on the municipality) and have been vaccinated against HPV in their teenage years.

Based on the study’s findings, low-risk HPV varieties are likely to be detected in these screenings. “So suddenly you have a reasonable number of women who at the screening are positive for HPV [types] which are included in the screening protocols typically, but are low risk. If you follow the standards of screening, those are considered positive, to be followed up on,” said Pimenoff.

HPV 33/35/52/56/58/66 are included in screenings as they are listed by the National Cancer Institute as high-risk, because they have been associated with malignancy. Yet the chances of them leading to cancer are much lower than the targeted types, and though there could be a concern that they may eventually become more oncogenic, the data so far don’t suggest they will.

“We also see that in these women – who have had in our cohort initial low risk type infection after vaccination – there is no sign of any progress,” said Pimenoff. “So in that sense, the data indicate the risk is very low or doesn’t exist.”

With such low-risk scenarios, the potential downsides include over-diagnosis and a waste of public health resources that could be redirected elsewhere, not to mention requiring women to undergo unnecessary testing, like additional Pap smears.

If screening post-vaccination becomes limited to high-oncogenic types, doing it less often would be sufficient, said Pimenoff – perhaps once every 10 years.

He noted, however, that recommendations can’t be the same everywhere, as “each country has its own status and a system on how to handle vaccination, screening, and the whole situation of what is the vaccine coverage”.

In the US in 2021, for example, 59% of adolescents between 13 and 15 had received two or three doses of the HPV vaccine according to recommendation guidelines, show the most recent available data.

Other researchers expressed more caution about the prospect of changing screening guidelines.

“I don’t think there are any immediate implications for screening or vaccine uptake. There are differences in gynaecological practice in the USA which some might say lead to a lot of over-treatment but the results here will not impact this issue significantly,” said Stern.

Still, the size and design of the study – particularly the fact that it included non-vaccinated cohorts, which are practically absent now in Finland – mean that it’s likely to be relevant for future policy discussions.

“While we should not rush to change screening policy as a result of one study, it would be prudent to check if these results are replicated elsewhere, and to consider the implications for which populations we screen and how we screen them,” said Stephen Duffy, professor of cancer screening at Queen Mary University of London.

Study details

Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts

Ville Pimenoff, Penelope Gray, Karolina Louvanto, Matti Lehtinen, et al.

Published in Cell Host & Microbe in volume 31 Issue 11

• Examination of the long-term effect of HPV vaccination on the ecology of untargeted HPVs
• Community-level depletion of vaccine-targeted HPV types occurs four years’ post-vaccination
• HPVs’ ecological diversity increases eight years’ post gender-neutral vaccination alone
• Observed ecological diversity increases despite the clearance of vaccine-targeted HPVs

The long-term effect of population-level human papillomavirus (HPV) vaccination on the viral ecology of the untargeted HPVs is poorly understood. We performed an eight-year follow-up of 33 communities randomised to gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and control communities without HPV vaccination. The 1992/93 and 1994 birth cohorts were invited in school years 2007/8 and 2008/9. Follow-up cervico-vaginal sampling at 18 and 22 years of age, 4 and 8 years post-vaccination, respectively, were attended by 11,396 and 5,602 participants. HPV types 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68 were genotyped and used for the community-level ecological diversity estimations. Gender-neutral vaccination communities with a stronger herd immunity than girls-only vaccination communities show a significantly increased HPV α-diversity (p = 1.1 × 10−8) from four to eight years’ post-vaccination, despite the clearance of the vaccine-targeted HPVs in these communities. This likely sign of niche occupation by the non-vaccine-targeted HPVs will potentially affect the future cervical cancer screening programs but should not interfere with the WHO mission to eliminate cervical cancer.


Cell Host & Microbe article – Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts (Open access)


STAT News article – HPV vaccines are so effective that new screening policies may be in order, suggests study (Open access)


See more from MedicalBrief archives:


One HPV jab effective for three years, gold-standard Kenya trial finds


HPV vaccine cuts cervical cancer by nearly 90% — UK population registry study


Vaccine could have prevented over 90% of HPV-related cancers


Teen boys in the UK to get HPV vaccination





MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.